AstraZeneca likely to conduct additional global trial to assess vaccine efficacy

AstraZeneca PLC is likely to conduct additional global trials to assess the efficacy of its COVID-19 vaccine, after current studies raised questions over its level of protection.

AstraZeneca’s trial results that they had released has been surrounded with criticism ever since they revealed that the lower doses regimen of the vaccine that had shown much higher efficacy was actually not by design of the trial but in error in dosing of the participants in UK and Brazil and that has raised serious questions around adherence to trail protocols and transparency of data.

Amidst all of these criticism AstraZeneca has now said that they are likely to go ahead with fresh global trials to assess if the lower dosing regimen actually sticks to the 90 percent efficacy that they have reported in a smaller set of participants.